申请人:——
公开号:US20030022939A1
公开(公告)日:2003-01-30
The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
1
to the said mammal.
The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.
本发明涉及一种刺激哺乳动物内皮NO合酶表达的方法,该方法包括向该哺乳动物施加4-氟-N-茚-2-基苯甲酰胺的生理活性量,其化学式为(I)1。该化合物(I)可用于治疗和预防心血管疾病,如稳定和不稳定性心绞痛,普林兹梅塔尔心绞痛(痉挛),急性冠状动脉综合征,心力衰竭,心肌梗死,中风,血栓形成,周围动脉闭塞性疾病PAOD,动脉粥样硬化,再狭窄,PTCA后的内皮损伤,原发性高血压,肺动脉高压,继发性高血压,肾血管性慢性肾小球肾炎,勃起功能障碍,室性心律失常以及降低绝经后妇女或口服避孕药后心血管风险的治疗和预防糖尿病和糖尿病并发症(肾病,视网膜病),血管生成,支气管哮喘,慢性肾衰竭,肝硬化,记忆力受限或学习能力受限。